🧾 What This Document Is 📄

This document is an Amendment to Form S-3, which is a legal filing with the SEC (Securities and Exchange Commission). Think of this form as a detailed instruction manual that Opus Genetics is providing to potential investors before they buy the company's stock.

The core purpose of this amendment is to register the sale of shares. This means the company is allowing existing large investors, called "selling stockholders," to sell a large block of shares to the public. The SEC filing process is designed to ensure transparency and protect investors.

👉 Why it matters: By filing this, Opus Genetics is initiating or confirming an offering of its common stock, meaning the company needs cash and is executing a strategy to raise capital.

🧬 What The Company Does 🧑‍🔬

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company. In simple terms, they are focused on developing cutting-edge gene therapies to treat inherited retinal diseases (IRDs) and other vision problems.

These therapies are a highly specialized and rapidly developing field of medicine. Instead of giving medication that manages symptoms, gene therapy aims to correct the fundamental genetic defects causing the disease.

👉 Key Focus: Their primary pipeline involves using adeno-associated virus (AAV)-based gene therapies. This technology delivers specific genetic instructions to the body's cells to help restore function in the retina.

🏥 Product Pipeline & Development Assets 🧬

The company has a focused pipeline containing three main assets, each targeting a different vision condition. The advanced stage of these programs is critical to their future value.

• LCA5 Gene Therapy: This is their most advanced gene therapy program. It is designed to address mutations in the LCA5 gene, which codes for the lebercilin protein. This treatment is currently being evaluated in a Phase 1/2 open-label, dose-escalation trial.
  • Why it matters: Phase 1/2 trials are crucial steps, as they show that the therapy is safe and begins to evaluate its effectiveness in humans.
• Phentolamine Ophthalmic Solution 0.75%: This solution acts as a non-selective alpha-1 and alpha-2 adrenergic antagonist, which helps reduce pupil size. It is currently being tested in Phase 3 trials for conditions like presbyopia (age-related vision changes) and dim (mesopic) light vision disturbances.
  • Why it matters: Being in Phase 3 trials is a very late, highly advanced stage that suggests clinical feasibility for treating vision problems.
• APX3330: This is a novel small-molecule inhibitor of Ref-1. It is being developed to slow the progression of non-proliferative diabetic retinopathy, a common complication of diabetes.

💸 The Private Placement of Shares 💰

The company recently executed a significant private funding round, called a Private Placement. This transaction established the immediate capital the company will use for research.

• The Transaction: On February 13, 2026, Opus Genetics entered into a securities purchase agreement with several investors (the “Purchasers”).
• The Amount Raised: The Purchasers bought 7,374,632 shares of Series B Preferred Stock at a price of $3.39 per share.
• Total Value: This transaction gave the company an aggregate purchase price of approximately $25.0 million.
• Purpose of Funds: Opus plans to use the net proceeds from this placement to advance its gene therapy clinical programs, as well as for general corporate and working capital purposes.

👉 Why it matters: The nearly $25 million infusion of cash provides the immediate financial runway needed to fund high-cost, long-term clinical development and research efforts.

📉 Shares Being Offered for Resale 📈

This S-3 filing is specifically about the resale of stock, meaning the shares are not being issued by the company itself.

• The Offering: The selling stockholders are offering up to 7,374,632 shares of common stock (par value $0.0001 per share).
• The Source: These shares are issuable upon the conversion of 7,374,632 shares of Series B Preferred Stock.
• The Legal Requirement: The company is registering this resale to satisfy a covenant (an agreement condition) set forth in a registration rights agreement that was entered into on February 18, 2026.
• The Selling Stockholders: The shares are being offered entirely by the selling stockholders.
  • Reminder: This means the company (Opus Genetics) itself will not receive any proceeds from the sale of these shares.

📐 Company Status and Compliance 📋

Opus Genetics is subject to specific regulatory classifications that impact how much disclosure they must provide.

• Smaller Reporting Company: The company has confirmed its status as a "smaller reporting company" under federal securities laws.
  • Why it matters: This status allows the company to use "scaled disclosures," which means they are allowed to comply with reduced public company reporting requirements, easing some of the reporting burdens.
• Location: The principal executive offices are located at 8 Davis Drive, Suite 220, Durham, NC 27713.
• Contact: The telephone number for the principal executive offices is (248) 957-9024.

🧑‍💼 Key Personnel and Governance 🤝

The filing lists the people responsible for the company's operations and governance as of the filing date (April 20, 2026).

• Executive Leadership:
  • Dr. George Magrath: Chief Executive Officer (and Principal Executive Officer/Director).
  • Robert Gagnon: Chief Financial Officer (CFO) (and Principal Financial Officer/Accounting Officer).
• Legal & Oversight: The filing also lists numerous directors, including Sean Ainsworth, Dr. Jean Bennett, Susan K. Benton, Cam Gallagher, Dr. Adrienne Graves, Dr. James S. Manuso, Richard J. Rodgers, and Dr. Benjamin R. Yerxa.
• Legal Counsel: The company engaged Sidley Austin LLP for legal services.

📅 Key Dates and Next Steps 🚀

This section details the commitments made to the investors regarding the timing of the stock sale and subsequent filings.

• Registration Rights Agreement: The company agreed to file an initial registration statement with the SEC no later than April 19, 2026 (the Filing Deadline).
• Expected Effectiveness: They have worked to have the full registration statement declared effective within 60 days of the earlier of the filing date or the Filing Deadline.
• Reporting History: Investors can find the Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 12, 2026.

🔍 Detailed Legal Mechanics (Registration Rights) 📜

The filing includes detailed legal language outlining the mechanisms of the sale, particularly the Registration Rights Agreement.

• The Obligation: Opus is obligated to prepare and file the Initial Registration Statement with the SEC.
• Indemnification: The company has agreed to indemnify the Purchasers and their representatives against certain liabilities arising from the registration rights agreement.
• Updates: The documents filed are subject to automatic updates; any future documents filed pursuant to specific sections of the Exchange Act will automatically update and supersede the information in this prospectus.

📄 Closing Documents and Contacts 📧

For investors who need more background information, the filing provides several ways to connect and review documents.

• Investor Relations Website: Details and more documents can be found on their website at www.opusgtx.com.
• Direct Filing Access: The SEC website (http://www.sec.gov) is where the full, most up-to-date filings can be accessed.
• Primary Contact: For direct inquiries, investors can reach the executive offices at: 8 Davis Drive, Suite 220, Durham, NC 27713 (248) 957-9024, Attention: Dr. George Magrath, Chief Executive Officer.

🧠 The Analogy 🧩

Think of this S-3 registration statement like getting a car sold at auction. Opus Genetics isn't selling the car itself; they are simply acting as the official agent who is legally allowed to manage the sale of a block of cars (shares) belonging to the original owners (selling stockholders). The transaction is necessary to raise cash that the company then uses to buy parts and fuel to keep the engineering department running (advancing the gene therapy programs).

🧩 Final Takeaway 🚀

Opus Genetics is actively raising capital by facilitating the resale of 7.37 million shares to fund its high-risk, high-reward gene therapy pipeline. The company's immediate focus is on advancing three key assets—especially the Phase 3 drug and the LCA5 gene therapy—using the capital raised in the recent Private Placement.